bioRxivBioengineeringPreprint
Small cell lung cancer co-culture organoids provide insights into cancer cell survival after chemotherapy
C. Sen, C. Koloff, S. Kundu, D. C. Wilkinson, J. Yang, D. W. Shia, L. K. Meneses, T. M. Rickabaugh, B. Gomperts
Abstract
Small-cell-lung-cancer (SCLC) has the worst prognosis of all lung cancers because of a high incidence of relapse after therapy. We developed a bioengineered 3-dimensional (3D) SCLC co-culture organoid as a phenotypic tool to study SCLC tumor kinetics and SCLC-fibroblast interactions during relapse. We used functionalized alginate microbeads as a scaffold to mimic lung alveolar architecture and co-cultured SCLC cell lines with primary adult lung fibroblasts (ALF). We found that SCLCs in the model proliferated extensively, invaded the microbead scaffold and formed tumors within just 7 days. We compared the bioengineered tumors with patient tumors and found them to recapitulate the pathology and immunophenotyping of the patient tumors better than the PDX model developed from the same SCLC cell line. When treated with standard chemotherapy drugs, etoposide and cisplatin, the organoid recapitulated relapse after chemotherapy. Co-culture of the SCLC cells with ALFs revealed that the fibroblasts play a key role in inducing faster and more robust SCLC cell regrowth in the model. This was a paracrine effect as conditioned medium from the same fibroblasts was responsible for this accelerated cell regrowth. This model is also amenable to high throughput phenotypic or targeted drug screening to find new therapeutics for SCLC.
- organism: human
- assay: organoid / primary culture
- research focus: cancer & tumor microenvironment
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Direct interaction between cancer cells and fibroblasts promotes early chemoresistance to standard-of-care drug therapy in small cell lung cancer (SCLC)
Nilu Dhungel, Brian Latimer, … Ana‐Maria Dragoi·bioRxiv·Apr 30, 2026
- Metastatic organotropism in small cell lung cancer
Manan Krishnamurthy, Anjali Dhall, … Anish Thomas·Journal of Thoracic OncologyPeer-reviewed·Aug 1, 2025
- Brief report on the development of patient-derived lung cancer organoids with keratinizing squamous cell carcinoma morphology
Eabha O'Sullivan, Christina Cahill, … Kathy A. Gately·bioRxiv·Apr 10, 2026
- Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugs
K. N. Suvilesh, Y. Manjunath, … J. T. Kaifi·bioRxiv·Oct 18, 2023
- A phase-field model for non-small cell lung cancer under the effects of immunotherapy
A. Wagner, P. Schlicke, … B. Wohlmuth·bioRxiv·Mar 20, 2023
- Microfluidic Platform for Drug Response Profiling in NSCLC Patient-Derived Organoids
Qiyue Luan, Alireza Rahnama, … Ian Papautsky·bioRxiv·Jun 19, 2026